Eli Lilly and Company $LLY Shares Bought by Calamos Advisors LLC

Calamos Advisors LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 13.2% in the 1st quarter, HoldingsChannel.com reports. The fund owned 308,497 shares of the company’s stock after acquiring an additional 35,943 shares during the quarter. Eli Lilly and Company comprises 1.0% of Calamos Advisors LLC’s holdings, making the stock its 12th biggest position. Calamos Advisors LLC’s holdings in Eli Lilly and Company were worth $283,746,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Spire Wealth Management boosted its holdings in shares of Eli Lilly and Company by 2.2% during the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after purchasing an additional 592 shares during the period. Coldstream Capital Management Inc. increased its stake in Eli Lilly and Company by 25.6% in the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after buying an additional 8,659 shares during the period. Farther Finance Advisors LLC increased its stake in Eli Lilly and Company by 30.8% in the 4th quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after buying an additional 7,338 shares during the period. Iams Wealth Management LLC purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $754,000. Finally, Militia Capital Partners LP lifted its position in Eli Lilly and Company by 333.3% in the 3rd quarter. Militia Capital Partners LP now owns 2,600 shares of the company’s stock worth $1,984,000 after buying an additional 2,000 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Guggenheim raised its price target on Eli Lilly to $1,273 and reiterated a Buy rating, reinforcing Wall Street’s confidence in the company’s growth outlook. Benzinga
• Positive Sentiment: Eli Lilly is presenting new Kisunla data at the Alzheimer’s Association International Conference, giving investors another potential pipeline catalyst beyond its blockbuster weight-loss drugs. Benzinga
• Positive Sentiment: Commentary around Eli Lilly’s obesity drugs continues to highlight how important the franchise is to revenue, with two products now generating nearly two-thirds of sales — a reminder of the company’s scale and earnings power. The Motley Fool
• Neutral Sentiment: Cathie Wood’s ARK funds added Eli Lilly alongside other large-cap names, which may signal continued institutional interest but is not a direct company-specific catalyst. Yahoo Finance
• Neutral Sentiment: Social-media and trading chatter remains upbeat, with investors citing upgraded targets and biotech momentum, but these comments are sentiment-driven rather than new fundamental disclosures. Quiver Quantitative
• Neutral Sentiment: A 247WallSt piece argues there may be a new under-the-radar catalyst in Eli Lilly’s pipeline, but it is largely speculative and not a confirmed development. 247WallSt

Wall Street Analysts Forecast Growth

Several research firms have recently commented on LLY. Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a report on Monday, June 22nd. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. Guggenheim boosted their target price on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research note on Monday. Finally, Morgan Stanley upped their target price on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,268.78.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,185.71 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $1.12 trillion, a price-to-earnings ratio of 42.12, a P/E/G ratio of 1.47 and a beta of 0.51. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,249.45. The firm has a 50 day moving average of $1,103.63 and a two-hundred day moving average of $1,034.03.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter last year, the firm earned $3.34 EPS. Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 35.81 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.